Literature DB >> 3127451

Detection of coronary artery reperfusion with creatine kinase-MB determinations during thrombolytic therapy: correlation with acute angiography.

H D Garabedian1, H K Gold, T Yasuda, J A Johns, D M Finkelstein, R J Gaivin, C Cobbaert, R C Leinbach, D Collen.   

Abstract

Increases in plasma creatine kinase-MB (MB CK) were correlated with the onset of coronary artery reperfusion determined angiographically in 32 patients with acute myocardial infarction who were treated with recombinant human tissue-type plasminogen activator (rt-PA). Reperfusion occurred in 14 (70%) of 20 patients with left anterior descending coronary artery occlusion and in 8 (73%) of 11 patients with right coronary artery occlusion. One patient had persistent left circumflex coronary artery occlusion. Plasma MB CK levels (radioimmunometric assay) did not increase significantly in patients with persistent occlusion, but increased by a mean (+/- SEM) of 8 +/- 1 and 6 +/- 1 times over pretreatment levels at the end of the infusion in patients with a reperfused left anterior descending and right coronary artery, respectively. When a greater than or equal to 2.5-fold increase in MB CK levels at the end of the rt-PA infusion was taken as evidence of reperfusion of the left anterior descending coronary artery, 13 (93%) of 14 patients with reperfusion and 5 (83%) of 6 with persistent occlusion were correctly identified. When a greater than or equal to 2.2-fold increase in MB CK levels was used to identify right coronary artery reperfusion, seven (89%) of eight patients with persistent occlusion were correctly identified. The sensitivity and specificity of these indexes, derived from and applied to the same patient group, were 91 and 89%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3127451     DOI: 10.1016/0735-1097(88)90204-5

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  11 in total

1.  ECG monitoring, biochemical Testing, and Anticoagulation Assessment.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

2.  Early, Complete Infarct Vessel Patency: Arriving at a Gold Standard for Future Clinical Investigation in Myocardial Reperfusion.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

3.  Evaluation of coronary artery patency using cardiac markers.

Authors:  Milenko J Tanasijevic
Journal:  J Thromb Thrombolysis       Date:  2005-02       Impact factor: 2.300

Review 4.  Biochemical markers of myocardial necrosis in acute myocardial infarction and thrombolysis.

Authors:  S Hornykewycz; H Gabriel; K Huber
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

5.  Enhanced thrombolytic efficacy and reduction of infarct size by simultaneous infusion of streptokinase and heparin.

Authors:  G Melandri; A Branzi; F Semprini; V Cervi; N Galiè; B Magnani
Journal:  Br Heart J       Date:  1990-08

6.  Assessment of coronary reperfusion in patients with myocardial infarction using fatty acid binding protein concentrations in plasma.

Authors:  M J de Groot; A M Muijtjens; M L Simoons; W T Hermens; J F Glatz
Journal:  Heart       Date:  2001-03       Impact factor: 5.994

7.  Are enzymatic tests good indicators of coronary reperfusion?

Authors:  H A Bosker; A van der Laarse; V M Cats; A V Bruschke
Journal:  Br Heart J       Date:  1992-02

8.  Non-invasive diagnosis of arterial patency after thrombolytic treatment and its relation to prognosis.

Authors:  R M Norris; H D White; D B Cross; K S Woo; J M Elliott; D Twigden; B Williams; R N Johnson
Journal:  Br Heart J       Date:  1993-06

9.  Transient release of lipid peroxidation products as a non-invasive marker of successful reperfusion after thrombolysis for myocardial infarction.

Authors:  H Ohlin; C G Gustavsson; E Pantev; B Thorvinger; A K Ohlin
Journal:  Br Heart J       Date:  1995-03

10.  Defibrotide versus heparin in the prevention of coronary reocclusion after thrombolysis in acute myocardial infarction.

Authors:  M Tubaro; G Mattioli; F Matta; C Cappello; E Natale; R Ricci; P Gerardi; F Milazzotto
Journal:  Cardiovasc Drugs Ther       Date:  1993-11       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.